Imperial College London

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Private

Established: 1907-07-08

Employees: 5K

Market Cap: -

Website: http://www.imperial.ac.uk

Clinical Trials

The Safety and Immunogenicity of a Potential HIV Vaccine

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: CN54gp140 mixed with GLA-AF

First Posted Date: 2013-10-22

Last Posted Date: 2019-11-07

Lead Sponsor: Imperial College London

Target Recruit Count: 14

Registration Number: NCT01966900

Locations: 🇬🇧
NIHR/Wellcome Trust Imperial Clinical Research Facility, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom

Non-invasive Pressure-Volume Analysis (NIPVA)

Completed

Conditions: Heart Failure

First Posted Date: 2013-10-11

Last Posted Date: 2022-04-11

Lead Sponsor: Imperial College London

Target Recruit Count: 65

Registration Number: NCT01960894

Locations: 🇬🇧
Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom

Effect of Cyclodextrin on Sensory Nerve Activity: A Novel Anti-tussive Therapy

Phase 4

Withdrawn

Conditions: Cough

Interventions: Drug: cyclodextrin

First Posted Date: 2013-10-10

Last Posted Date: 2019-05-23

Lead Sponsor: Imperial College London

Registration Number: NCT01960621

Locations: 🇬🇧
Asthma Lab, Royal Brompton Hospital, London, United Kingdom

Gut Hormones and Roux en Y Gastric Bypass

Not Applicable

Recruiting

Conditions: Type 2 Diabetes
Obesity

Interventions: Other: Placebo infusion
Procedure: Roux en Y Gastric Bypass Surgery
Other: Gut hormone infusion
Other: Very low calorie diet

First Posted Date: 2013-09-19

Last Posted Date: 2021-04-20

Lead Sponsor: Imperial College London

Target Recruit Count: 190

Registration Number: NCT01945840

Locations: 🇬🇧
NIHR/Wellcome Trust Imperial CRF, Hammersmith Hospital, London, Greater London, United Kingdom

Effect of Neuromuscular Calf Stimulation and Intermittent Pneumatic Compression on Lower Limb Venous Hemodynamics

Not Applicable

Completed

Conditions: Intermittent Pneumatic Compression

Interventions: Device: Intermittent pneumatic compression, followed by neuromuscular stimulation
Device: Neuromuscular stimulation, followed by intermittent pneumatic compression

First Posted Date: 2013-09-11

Last Posted Date: 2019-09-20

Lead Sponsor: Imperial College London

Target Recruit Count: 10

Registration Number: NCT01939288

Locations: 🇬🇧
Academic Vascular Surgery, Charing Cross Hospital, London, United Kingdom

Investigating Brown Adipose Tissue Activation in Humans

Not Applicable

Completed

Conditions: Metabolic Diseases

Interventions: Drug: Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon
Other: Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative
Other: Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle
Drug: Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon
Drug: Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control
Drug: Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control
Drug: Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control
Drug: Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon
Drug: Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control

First Posted Date: 2013-09-05

Last Posted Date: 2021-05-18

Lead Sponsor: Imperial College London

Target Recruit Count: 11

Registration Number: NCT01935791

Locations: 🇬🇧
Imperial College London, London, United Kingdom

Surgery in Persons of Older Age

Conditions: Colorectal Disorders
Quality of Life
Surgery
Old Age; Debility
Complications

First Posted Date: 2013-08-16

Last Posted Date: 2015-03-26

Lead Sponsor: Imperial College London

Target Recruit Count: 200

Registration Number: NCT01924585

Locations: 🇬🇧
St Mary's Hospital, London, United Kingdom
🇬🇧
St Mark's Hospital, Northwick Park NHS Trust, Harrow, Middlesex, United Kingdom

Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses

Phase 1

Completed

Conditions: HIV

Interventions: Biological: DNA
Biological: MVA-C
Biological: CN54rgp140
Biological: GLA-AF

First Posted Date: 2013-08-14

Last Posted Date: 2016-09-27

Lead Sponsor: Imperial College London

Target Recruit Count: 40

Registration Number: NCT01922284

Locations: 🇬🇧
Imperial College London, Greater London, United Kingdom
🇬🇧
Surrey Clinical Research Centre, University of Surrey, Guildford, Surrey, United Kingdom